Global Connected Injectable Drug Delivery Devices Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Connected Injectable Drug Delivery Devices Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Connected Injectable Drug Delivery Devices market finds that the global Connected Injectable Drug Delivery Devices market reached a value of USD 706.98 million in 2022. It’s expected that the market will achieve USD 1849.46 million by 2028, exhibiting a CAGR of 17.38% during the forecast period.

Market Challenges

To date, the development and adoption of connected drug delivery devices have been relatively limited. Typically, connected injection devices are used to compete for high-value drugs in chronic diseases such as multiple sclerosis (MS), human growth hormone deficiency and diabetes, which are often already supported by patient support programs. Integrating connected devices into these existing procedures improves patient engagement, enables more evidencebased patient guidance, and allows providers to zero the patients most in need. However, expanding these interventions and applying them to a wider range of healthcare practices remains challenging.

Region Overview:

From 2023-2028, Europe is estimated to witness robust growth prospects.

Company Overview:

The top three companies are Merck Serono, Bayer and Amgen with the revenue market share of 30.66%, 19.95% and 18.39% in 2018.

EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany, employing over 1,200 individuals around the country with U.S. headquarters located in Rockland, Massachusetts. The company develops and offers therapies for specialty-care conditions, like multiple sclerosis, infertility and cancer. EMD Serono is committed to transforming lives by developing therapies that patients need and providing industry-leading educational and support programs.

Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Its products and services are designed to benefit people and improve their quality of life. At the same time, Bayer aims to create value through innovation, growth and high earning power.

Segmentation Overview:

Among different product types, Self-Injection segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Autoimmune Diseases segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Connected Injectable Drug Delivery Devices market covered in Chapter 3:

Bayer
Amgen
Merck Serono
West Pharmaceutical Services

In Chapter 4 and Chapter 14.2, on the basis of types, the Connected Injectable Drug Delivery Devices market from 2018 to 2029 is primarily split into:

Conventional
Self-Injection
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Connected Injectable Drug Delivery Devices market from 2018 to 2029 covers:

Diabetes
Cardiovascular Diseases
Autoimmune Diseases
Hormones Replacement
Neurology
Addiction
Respiratory Diseases
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)